Future COVID Vaccines Have to Be Far better Science Races to Respond

SOURCES 

David L. Hoey, president and CEO of Vaxxas, Cambridge, MA, and Brisbane, Australia.

Pablo Penaloza-MacMaster, PhD, assistant professor of microbiology and immunology, Feinberg College of Medicine, Northwestern University, Chicago.

Jasdave Chahal, PhD, co-founder and chief scientist, Tiba Biotech, Cambridge, MA, and Brisbane, Australia.

Vaxart news release: “Vaxart Announced Optimistic Top rated-line Phase II clinical Study Information Demonstrating Safaety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate.”

Mark Herr, spokesperson, Vaxart Inc. 

The Commonwealth Fund: “Two Years of  U.S. COVID-19 Vaccines Have Prevented Millions of Hospitalizations and Deaths.”

The Lancet Infectious Ailments: “Global influence of the very first year of COVID-19 vaccination: a mathematical modelling study.” 

CDC: COVID Information Tracker, “Needle Fears and Phobias—Find Techniques to Handle.”

U.S. Specialty Formulations news release: “Research Demonstrates Advantages of Oral COVID-19 Vaccine.”

CanSino Biologics Inc. statement: “Inside Data.” 

Coalition for Epidemic Preparedness Innovations:  E mail statement News releases: “The Race to Future-Proof Coronavirus Vaccines.”  “Coming in from the cold: needle-no cost patch technologies for mRNA vaccines aims to finish will need for frozen storage and strengthen access.” 

Executive Workplace of  the President: “Statement of Administration Policy.”

Science: “Mosaic RBD nanoparticles guard against challenge by diverse sarbecoviruses in animal models.”

Caltech news release: “Nanoparticle Vaccine Protects Against a Spectrum of COVID-19-causing Variants and Associated Viruses.”   

U.S. Government Accountability Workplace. “Operation Warp Speed.”

Bharat Biotech International Restricted news release: “Bharat biotech launches iNCOVACC: World’s 1st intranasal COVID vaccine for Principal series and Heterologous booster.” 

The Lancet preprints: “Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-two Vaccine, Compared with Intramuscular Covaxin® in Wholesome Adults: A Randomised, Open-Label, Phase three Clinical Trial.”

Cell: “Intranasal pediatric parainfluenza virus-vectored SARS-CoV-two vaccine is protective in monkeys.”

National Institute of Allergy and Infectious Ailments news release: “NIAID Problems Additional Awards to Assistance Pan-Coronavirus Vaccine Improvement.”

CEPI news release: “CEPI and DIOSynVax companion in quest to create broadly protective Betacoronavirus vaccine.” 

CDC: “Understanding How COVID-19 Vaccines Function.” 

Nature Immunology: “The T-cell immune response against SARS-CoV-two.”

National Institutes of Wellness: “T cells guard against COVID-19 in absence of antibody response.”

PNAS: “Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-two viral variants.”

Cell Reports: “Pre-current immunity modulates responses to mRNA boosters.”

University of Minnesota Center for Infectious Illness Investigation and Policy: “Coronavirus Vaccines R&ampD Roadmap.”

NIH news release: “2NIAID Research Highlight COVID-ten Natal Vaccine Possible.”

U.S. Specialty Formulations news release: “Research demonstrates advantages of oral COVID-19 vaccine.”